Scientelle CSI-221

SCI-221 is a novel vaginal gel, formulated under the patent that now is issued in more that 40 countries. It provides for a targeted antibacterial effect against pathogens associated with Bacterial Vaginosis and establishes an environment supportive to Lactobacilli, thus creating an opportunity for normalization of vaginal microbiota. The source of peroxide used in SCI-221 has a proven safety record in different indications. The core technology providing for patented synergistic effect builds on the success of several FDA-approved products, adding to a low risk development environment. A robust in-vitro proof-of-concept program, completed in 2013 http://dx.doi.org/10.1155/2013/909354 clearly demonstrated that SCI-221, our non-antibiotic product for treatment and prevention of Bacterial Vaginosis has a required selectivity and kinetics of antibacterial effect. Now we are rapidly moving into the clinical phase and are seeking investment to support the expedited completion of clinical proof-of-concept.